Home Toward Evidence-based Decisions in Diagnostic Radiology
Post
Cancel

Toward Evidence-based Decisions in Diagnostic Radiology

The use of diagnostic imaging tests and the development of evidence-based guidelines, reviews, and other materials have both undergone substantial growth in recent years. However, the proliferation of evidence-based information has not translated into the universal deployment of medical and coverage policy for diagnostic imaging that is similarly evidence-based. One possible reason is the failure of those institutions generating evidence-based information to format findings in an accessible manner for all relevant stakeholders. The Institute for Clinical and Economic Review has developed a simple and transparent method for rating evidence that is accessible to clinicians, patients, payers, and other policy makers. The authors describe this process in relation to three imaging-based examples (computed tomographic colonography, coronary computed tomographic angiography, and positron emission tomography for dementia neuropathology). The issues raised, controversies considered, and use of the ratings in setting policy are discussed in relation to each example.

The past decade has featured remarkable growth in the use of the common tools and outputs of evidence-based medicine, defined as “the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients” . The publication of systematic reviews and meta-analyses, the preferred methodologic approach for synthesizing published evidence on the effects of medical interventions, grew by >60% between 2005 and 2009 . Similarly, medical societies and other purveyors of clinical practice guidelines, including the American College of Radiology, are increasingly describing their products as evidence-based .

During this same time period, there has also been an unprecedented increase in the use of diagnostic imaging. Annual increases in the use of computed tomography, magnetic resonance imaging, and other advanced imaging services are estimated to range from 8% to 10% in the Medicare population alone ; Medicare expenditures for these services more than doubled between 2000 and 2006 . Multiple factors have been associated with this growth, including financial incentives for physician ownership of imaging devices, increased patient and clinician self-referral, and increased imaging capacity , none of which is well correlated with acceptance of evidence-based information to guide clinical practice.

Indeed, the submission of and payment for imaging claims appear to be largely independent of any concept of suitability for patients, despite the presence of well-accepted guidelines on appropriate imaging practice. A cross-sectional study of the American College of Radiology (ACR) Appropriateness Criteria and Medicare Part B payments for neurologic imaging found that although the most appropriate tests were twice as likely to be reimbursed as the least appropriate tests, nearly two thirds of claims for tests with “low” appropriateness for a given condition were nevertheless paid .

So why has the explosion in evidence-based research not resulted in widespread acceptance by decision makers to modulate imaging utilization? It is certainly possible that the variability in what is described as “evidence” is simply too broad to engender the universal trust of clinicians. A cross-sectional analysis of >300 treatment recommendations in cardiovascular management guidelines indicated that fewer than half of these recommendations were based on “high-quality” evidence . In addition, and in a reflection of what is found in the medical literature, many imaging guidelines focus on choices between diagnostic modalities, rather than addressing whether such testing should be performed at all. For example, the widely disseminated ACR Appropriateness Criteria provide detailed guidance on choice of imaging modality but are inconsistent on the question of whether imaging is even appropriate for a given circumstance. Finally, there is some indication that the study of gaps between evidence and practice has remained relatively constant over time, with relatively little attention paid to developing interventions to address these gaps .

However, it may also be the case that evidence-based data on appropriate imaging use are not universally accessible to all relevant stakeholders. For example, clinical guideline documents are rarely presented in a fashion that is digestible by patients. In addition, public and private payers may use very different approaches to estimating the potential benefit of diagnostic imaging, preferring to focus on efficiencies in clinical practice gained and improvement in long-term outcomes over the test performance statistics and other intermediate outcomes produced by most trials of imaging technologies.

Get Radiology Tree app to read full this article<

The institute for clinical and economic review approach

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Rating Comparative Clinical Effectiveness

Get Radiology Tree app to read full this article<

Figure 1, Evidence-based medicine matrix for rating evidence on comparative clinical effectiveness. A = superior: high certainty of a moderate to large net health benefit; B = incremental: high certainty of a small net health benefit; C = comparable: high certainty of a comparable net health benefit; D = inferior: high certainty of an inferior net health benefit; U/P = unproven with potential: moderate certainty of a small or moderate to large net health benefit (this category is meant to reflect technologies whose evidence provides high certainty of at least comparable net health benefit or moderate certainty suggesting a small or moderate to large net health benefit); I = insufficient: the evidence does not provide high certainty that the net health benefit of the technology is at least comparable to that provided by the comparator(s).

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Rating Comparative Value

Get Radiology Tree app to read full this article<

Table 1

Measures of Economic Impact Considered in Appraisals Conducted by the Institute for Clinical and Economic Review

Measure Of Primary Interest to Resource use (eg, test frequency, need for hospitalization) Patients, clinicians Cost to achieve treatment success Clinicians Cost to prevent adverse outcome Clinicians Cost per life-year gained Policy makers, payers Cost per quality-adjusted life-year gained Policy makers, payers Budgetary impact Payers, health systems Manpower trade-offs Health systems

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Integrated Evidence Rating

Get Radiology Tree app to read full this article<

Figure 2, Institute for Clinical and Economic Review integrated evidence rating matrix.

Get Radiology Tree app to read full this article<

Case studies using the institute for clinical and economic review rating approach

Get Radiology Tree app to read full this article<

Computed Tomographic Colonography (CTC)

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Impact of appraisal

Get Radiology Tree app to read full this article<

Coronary Computed Tomographic Angiography (CCTA)

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Impact of appraisal

Get Radiology Tree app to read full this article<

Positron Emission Tomography for Dementia Neuropathology

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Conclusions

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

Get Radiology Tree app to read full this article<

References

  • 1. Sackett D., Rosenberg W., Gray J., et. al.: Evidence based medicine: what it is and what it isn’t. BMJ 1996; 312: pp. 71-72.

  • 2. Bastian H., Glasziou P., Chalmers I.: Seventy-five trials and eleven systematic reviews a day: how will we ever keep up?. PLoS Med 2010; 7: pp. e1000326.

  • 3. American College of Radiology. ACR Appropriateness Criteria®. Available at: http://www.acr.org/ac . Accessed June 3, 2012.

  • 4. Bhargavan M., Sunshine J.H.: Utilization of radiology services in the United States: Levels and trends in modalities, regions, and populations. Radiology 2005; 234: pp. 824-832.

  • 5. US Government Accountability Office : Medicare: trends in fees, utilization, and expenditures for imaging services before and after implementation of the Deficit Reduction Act of 2005.2008.US Government Accountability OfficeWashington, DC

  • 6. Mongan J.J., Ferris T.G., Lee T.H.: Options for slowing the growth of health care costs. N Engl J Med 2008; 358: pp. 1509-1514.

  • 7. Levin D.C., Rao V.M., Kaye A.: Turf wars in radiology: recent actions against self-referral by state governments, commercial payers, and Medicare—hope is on the horizon. J Am Coll Radiol 2008; 5: pp. 972-977.

  • 8. Sistrom C.L., McKay N.L.: Evidence-based imaging guidelines and Medicare payment policy. Health Serv Res 2008; 43: pp. 1006-1024.

  • 9. McAlister F.A., van Diepen S., Padwal R.S., et. al.: How evidence-based are the recommendations in evidence-based guidelines?. PLoS Med 2007; 4: pp. e250.

  • 10. Evensen A.E., Sanson-Fisher R., D’Este C., et. al.: Trends in publications regarding evidence-practice gaps: a literature review. Implement Sci 2010; 5: pp. 11.

  • 11. Ollendorf D.A., Pearson S.D.: An integrated evidence rating to frame comparative effectiveness assessments for decision makers. Med Care 2010; 48: pp. S145-S152.

  • 12. Sawaya G.F., Guirguis-Blake J., LeFebre M., et. al.: Update on the methods of the US Preventive Services Task Force. Ann Intern Med 2007; 147: pp. 871-875.

  • 13. Scherer R, Knudsen A, Pearson SD. Final appraisal document: CT colonography for colorectal cancer screening. Available at: http://www.icer-review.org/index.php/Reports/ctc.html . Accessed June 3, 2012.

  • 14. Blackmore C.C., Budenholzer B.: Applying evidence-based imaging to policy: the Washington state experience. J Am Coll Radiol 2009; 6: pp. 366-371.

  • 15. Pearson S.D., Knudsen A., Scherer R.W., et. al.: Assessing the comparative effectiveness of a diagnostic technology: CT colonography. Health Aff (Millwood) 2008; 27: pp. 1503-1514.

  • 16. Nicholson F.B., Barro J.L., Bartram C.I., et. al.: The role of CT colonography in colorectal cancer screening. Am J Gastroenterol 2005; 100: pp. 2315-2323.

  • 17. Deeks J.J.: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323: pp. 157-162.

  • 18. Washington State Health Care Authority. Health Technology Clinical Committee: findings and coverage decision. Available at: http://www.hta.hca.wa.gov/documents/decision_finding_vc_final_090308.pdf . Accessed June 3, 2012.

  • 19. Ollendorf DA, Göhler A, Pearson SD, et al. Final appraisal document: coronary computed tomographic angiography for detection of coronary artery disease. Available at: http://www.icer-review.org/index.php/Reports/ccta.html . Accessed June 3, 2012.

  • 20. Washington State Health Care Authority. Health Technology Clinical Committee: findings and coverage decision. Available at: http://www.hta.hca.wa.gov/documents/findings_decision_ccta_051209.pdf . Accessed June 3, 2012.

  • 21. Goldstein J.A., Gallagher M.J., O’Neill W.W., et. al.: A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol 2007; 49: pp. 863-871.

  • 22. Ollendorf D.A., Kuba M., Pearson S.D.: The diagnostic performance of multi-slice coronary computed tomographic angiography: a systematic review. J Gen Intern Med 2010; 26: pp. 307-316.

  • 23. Budoff M.J., Dowe D., Jollis J.G., et. al.: Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. J Am Coll Cardiol 2008; 52: pp. 1724-1732.

  • 24. Miller J.M., Rochitte C.E., Dewey M., et. al.: Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 2008; 359: pp. 2324-2336.

  • 25. Meijboom W.B., Meijs M.F., Schuijf J.D., et. al.: Diagnostic accuracy of 64-slice computed tomography coronary angiography. J Am Coll Cardiol 2008; 52: pp. 2135-2144.

  • 26. Freundlich N. Diagnosis without treatment: the perils of new tests for early Alzheimer’s disease. Available at: http://www.healthbeatblog.com/2010/07/diagnosis-without-treatment-the-perils-of-new-tests-for-early-alzheimers-disease.html . Accessed December 22, 2011.

  • 27. Pepe M.S.: The Statistical Evaluation of Medical Tests for Classification and Prediction.2003.Oxford University PressNew York

  • 28. Obuchowski N.A., Graham R.J., Baker M.E., et. al.: Ten criteria for effective screening: their application to multislice CT screening for pulmonary and colorectal cancers. AJR Am J Roentgenol 2001; 176: pp. 1357-1362.

  • 29. Birks J.: Cholinesterase inhibitors for Alzheimer’s disease (review). Cochrane Database Syst Rev 2006; 25: pp. CD005593.

  • 30. Loy C., Schneider L.: Galantamine for Alzheimer’s disease and mild cognitive impairment (review). Cochrane Database Syst Rev 2006; 25: pp. CD001747.

  • 31. Mattson N., Zetterberg H.: Future screening for incipient Alzheimer’s disease—the influence of prevalence on test performance. Eur Neurol 2009; 62: pp. 200-203.

  • 32. Lee D.W., Neumann P.J., Rizzo J.A.: Understanding the medical and nonmedical value of diagnostic testing. Value Health 2010; 13: pp. 310-314.

This post is licensed under CC BY 4.0 by the author.